An update on pediatric bronchiectasis

Danielle F. Wurzel, Anne B. Chang

    Research output: Contribution to journalReview articleResearchpeer-review

    Abstract

    Introduction: The prevalence and awareness of bronchiectasis not related to cystic fibrosis (CF) is increasing and it is now recognized as a major cause of respiratory morbidity, mortality and healthcare utilization worldwide. The need to elucidate the early origins of bronchiectasis is increasingly appreciated and has been identified as an important research priority. Current treatments for pediatric bronchiectasis are limited to antimicrobials, airway clearance techniques and vaccination. Several new drugs targeting airway inflammation are currently in development. 

    Areas covered: Current management of pediatric bronchiectasis, including discussion on therapeutics, non-pharmacological interventions and preventative and surveillance strategies are covered in this review. We describe selected adult and pediatric data on bronchiectasis treatments and briefly discuss emerging therapeutics in the field. 

    Expert commentary: Despite the burden of disease, the number of studies evaluating potential treatments for bronchiectasis in children is extremely low and substantially disproportionate to that for CF. Research into the interactions between early life respiratory tract infections and the developing immune system in children is likely to reveal risk factors for bronchiectasis development and inform future preventative and therapeutic strategies. Tailoring interventions to childhood bronchiectasis is imperative to halt the disease in its origins and improve adult outcomes.

    Original languageEnglish
    Pages (from-to)517-532
    Number of pages16
    JournalExpert Review of Respiratory Medicine
    Volume11
    Issue number7
    DOIs
    Publication statusPublished - 3 Jul 2017

    Fingerprint

    Bronchiectasis
    Pediatrics
    Cystic Fibrosis
    Therapeutics
    Drug Delivery Systems
    Research
    Respiratory Tract Infections
    Immune System
    Vaccination
    Inflammation
    Morbidity
    Delivery of Health Care
    Mortality

    Cite this

    Wurzel, Danielle F. ; Chang, Anne B. / An update on pediatric bronchiectasis. In: Expert Review of Respiratory Medicine. 2017 ; Vol. 11, No. 7. pp. 517-532.
    @article{65cd702d6cac4d1fa5f251db343afe7e,
    title = "An update on pediatric bronchiectasis",
    abstract = "Introduction: The prevalence and awareness of bronchiectasis not related to cystic fibrosis (CF) is increasing and it is now recognized as a major cause of respiratory morbidity, mortality and healthcare utilization worldwide. The need to elucidate the early origins of bronchiectasis is increasingly appreciated and has been identified as an important research priority. Current treatments for pediatric bronchiectasis are limited to antimicrobials, airway clearance techniques and vaccination. Several new drugs targeting airway inflammation are currently in development. Areas covered: Current management of pediatric bronchiectasis, including discussion on therapeutics, non-pharmacological interventions and preventative and surveillance strategies are covered in this review. We describe selected adult and pediatric data on bronchiectasis treatments and briefly discuss emerging therapeutics in the field. Expert commentary: Despite the burden of disease, the number of studies evaluating potential treatments for bronchiectasis in children is extremely low and substantially disproportionate to that for CF. Research into the interactions between early life respiratory tract infections and the developing immune system in children is likely to reveal risk factors for bronchiectasis development and inform future preventative and therapeutic strategies. Tailoring interventions to childhood bronchiectasis is imperative to halt the disease in its origins and improve adult outcomes.",
    keywords = "Bronchiectasis, children, cough, treatment",
    author = "Wurzel, {Danielle F.} and Chang, {Anne B.}",
    year = "2017",
    month = "7",
    day = "3",
    doi = "10.1080/17476348.2017.1335197",
    language = "English",
    volume = "11",
    pages = "517--532",
    journal = "Expert Review of Respiratory Medicine",
    issn = "1747-6348",
    publisher = "Expert Reviews",
    number = "7",

    }

    An update on pediatric bronchiectasis. / Wurzel, Danielle F.; Chang, Anne B.

    In: Expert Review of Respiratory Medicine, Vol. 11, No. 7, 03.07.2017, p. 517-532.

    Research output: Contribution to journalReview articleResearchpeer-review

    TY - JOUR

    T1 - An update on pediatric bronchiectasis

    AU - Wurzel, Danielle F.

    AU - Chang, Anne B.

    PY - 2017/7/3

    Y1 - 2017/7/3

    N2 - Introduction: The prevalence and awareness of bronchiectasis not related to cystic fibrosis (CF) is increasing and it is now recognized as a major cause of respiratory morbidity, mortality and healthcare utilization worldwide. The need to elucidate the early origins of bronchiectasis is increasingly appreciated and has been identified as an important research priority. Current treatments for pediatric bronchiectasis are limited to antimicrobials, airway clearance techniques and vaccination. Several new drugs targeting airway inflammation are currently in development. Areas covered: Current management of pediatric bronchiectasis, including discussion on therapeutics, non-pharmacological interventions and preventative and surveillance strategies are covered in this review. We describe selected adult and pediatric data on bronchiectasis treatments and briefly discuss emerging therapeutics in the field. Expert commentary: Despite the burden of disease, the number of studies evaluating potential treatments for bronchiectasis in children is extremely low and substantially disproportionate to that for CF. Research into the interactions between early life respiratory tract infections and the developing immune system in children is likely to reveal risk factors for bronchiectasis development and inform future preventative and therapeutic strategies. Tailoring interventions to childhood bronchiectasis is imperative to halt the disease in its origins and improve adult outcomes.

    AB - Introduction: The prevalence and awareness of bronchiectasis not related to cystic fibrosis (CF) is increasing and it is now recognized as a major cause of respiratory morbidity, mortality and healthcare utilization worldwide. The need to elucidate the early origins of bronchiectasis is increasingly appreciated and has been identified as an important research priority. Current treatments for pediatric bronchiectasis are limited to antimicrobials, airway clearance techniques and vaccination. Several new drugs targeting airway inflammation are currently in development. Areas covered: Current management of pediatric bronchiectasis, including discussion on therapeutics, non-pharmacological interventions and preventative and surveillance strategies are covered in this review. We describe selected adult and pediatric data on bronchiectasis treatments and briefly discuss emerging therapeutics in the field. Expert commentary: Despite the burden of disease, the number of studies evaluating potential treatments for bronchiectasis in children is extremely low and substantially disproportionate to that for CF. Research into the interactions between early life respiratory tract infections and the developing immune system in children is likely to reveal risk factors for bronchiectasis development and inform future preventative and therapeutic strategies. Tailoring interventions to childhood bronchiectasis is imperative to halt the disease in its origins and improve adult outcomes.

    KW - Bronchiectasis

    KW - children

    KW - cough

    KW - treatment

    UR - http://www.scopus.com/inward/record.url?scp=85020488164&partnerID=8YFLogxK

    U2 - 10.1080/17476348.2017.1335197

    DO - 10.1080/17476348.2017.1335197

    M3 - Review article

    VL - 11

    SP - 517

    EP - 532

    JO - Expert Review of Respiratory Medicine

    JF - Expert Review of Respiratory Medicine

    SN - 1747-6348

    IS - 7

    ER -